Weight Management News and Research

RSS

Higher ultra-processed food intake aligns with greater binge eating risk in obesity study

Higher intake of ultra-processed foods in adults with obesity was associated with disordered eating symptoms, poorer diet quality, and lower protein intake. The cross-sectional findings suggest dietary processing level may influence eating behaviour patterns relevant to obesity management, though causality cannot be inferred.

23 Feb 2026

Big breakfast study reveals protein curbs appetite but fiber delivers stronger gut microbiome benefits

A randomized crossover weight loss trial in adults with overweight or obesity found that higher protein big breakfasts improved satiety, while higher fibre breakfasts produced slightly greater weight loss and more favourable gut microbiota markers. Both diets improved metabolic biomarkers, but microbiota changes reflected surrogate gut health indicators rather than direct clinical outcomes.

15 Feb 2026

Ozempic users continue treatment when weight loss works despite side effects

A study on Ozempic for weight loss reveals user satisfaction is driven by efficacy, despite common gastrointestinal side effects impacting treatment adherence.

13 Feb 2026

Obesity drives shared genetic risk behind many chronic disease combinations

The study uncovers obesity's genetic links to chronic diseases, offering insights into multimorbidity and the potential for targeted health interventions.

9 Feb 2026

Moderate exercise lowers atrial fibrillation recurrence after ablation

New research from CU Anschutz scientists suggests that staying physically active after heart rhythm treatment may significantly reduce the risk of atrial fibrillation (AF) returning, offering patients a simple, low-cost way to support long-term heart health.

7 Feb 2026

New role for GLP-1 drugs: Improving survival in people with severe psychiatric disorders

This editorial argues that GLP-1 receptor agonists could substantially improve healthspan and reduce premature mortality in people with serious mental illnesses by targeting cardiometabolic risk rather than psychiatric symptoms alone. It highlights emerging evidence, safety considerations, and equity challenges that position GLP-1 RAs as a promising public health strategy for this high-risk population.

25 Jan 2026

Unraveling liver injury mechanisms in familial hypobetalipoproteinemia

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal co-dominant monogenic disorder characterized by lifelong low plasma levels of total cholesterol, low-density lipoprotein cholesterol (LDL-C), and APOB.

24 Jan 2026

Menopausal hormone therapy linked to greater weight loss with tirzepatide

A new study led by Mayo Clinic found that postmenopausal women receiving menopausal hormone therapy lost 35% more weight while taking tirzepatide, a Food and Drug Administration-approved drug for the treatment of overweight and obesity.

22 Jan 2026

Algae may help meet future protein demand without straining the planet

This narrative review evaluates clinical evidence on algae and algal proteins as sustainable, nutrient-dense food sources with high protein quality and bioactive compounds. Findings suggest potential benefits for muscle protein synthesis, cardiometabolic markers, immune modulation, and antioxidant status, while emphasizing heterogeneity, short-term data, and the need for longer clinical trials.

20 Jan 2026

Most patients regain lost weight within two years of stopping obesity drugs

Weight management medications show limited long-term effects, with rapid weight regain post-treatment, emphasizing the need for sustainable obesity strategies.

13 Jan 2026

Why some people can’t lose weight even when they follow the rules

New research reveals biological factors, not just effort, influence weight loss success, highlighting the need for personalized diet and exercise interventions.

13 Jan 2026

Why adherence determines weight loss success with semaglutide

Researchers examine how the effectiveness of weight-loss medications may depend on the patient adherence.

12 Jan 2026

George Mason trial: New pill aims to sustain weight loss after GLP-1s

GLP-1 medications like Ozempic and Wegovy have transformed obesity treatment, but maintaining weight loss after the medications stop remains a challenge.

9 Jan 2026

California ends Medicaid coverage of weight loss drugs despite TrumpRx plan

Many low-income Californians prescribed wildly popular weight loss drugs lost their coverage for the medications at the start of the new year.

9 Jan 2026

Global analysis shows widespread eligibility for GLP-1 weight management drugs

The worldwide prevalence of obesity has more than doubled in the last three decades, bringing with it an increase in weight-related diseases like diabetes, cardiovascular disease, and cancers.

8 Jan 2026

Weight loss drugs may cause nutritional deficiencies without proper guidance

People prescribed the new generation of weight loss drugs may not receive sufficient nutritional guidance to support safe and sustainable weight loss, leaving them vulnerable to nutritional deficiencies and muscle loss, say experts at UCL and the University of Cambridge.

7 Jan 2026

Millions in Great Britain using or seeking weight loss drugs

An estimated 1.6 million adults in England, Wales and Scotland used drugs such as Wegovy and Mounjaro to help lose weight between early 2024 and early 2025, according to a new study by UCL (University College London) researchers.

7 Jan 2026

Stopping weight loss drugs leads to rapid weight regain and health reversal

Stopping weight loss drugs is followed by weight regain and reversal of beneficial effects on heart and metabolic health markers such as high cholesterol and high blood pressure, finds a study published by The BMJ today.

7 Jan 2026

Depression links to chronic headaches through weight and diet, not physical activity alone

Depression was associated with a higher likelihood of chronic headaches in Iranian adults, with statistical models identifying body mass index and dietary iron intake as partial mediators. Physical activity was linked to depression but did not independently mediate headache outcomes, highlighting interconnected, non-causal pathways.

1 Jan 2026

How diabetes medications may influence cancer risk and progression

Diabetes, particularly Type 2 Diabetes (T2DM), has been linked to an increased risk of various cancers, including liver, colorectal, and breast cancer.

18 Dec 2025